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1 Introduction
The fact that individuals are diﬀerent is a fundamental observation of life. Some
diﬀerences are obviously important, like being a female compared to a male, if
you are to bear a child. Other diﬀerences are more subtle, and harder to observe.
Genetic predisposition towards a disease is one example. A population consists of
a mix of individuals, where some may have a high risk, some may have a low risk,
or some may even be immune to the outcome we are studying. We say that the
population is heterogeneous.
Survival data, consisting of the time from some starting point to an event,
is frequently encountered in a large range of ﬁelds, from medicine to economics.
Survival analysis, that comprises the statistical tools for analyzing such data, has
become very important. Of special importance is the hazard rate, which expresses
the instantaneous rate of having an event at a particular time (given survival up
to that time). For many, the method of choice for handling survival data, is the
Cox proportional hazards model [1]. The model allows for the inclusion of indi-
viduals that are lost to follow-up, i.e. censored, and the population is divided into
subgroups by diﬀerent covariates that we suspect to have an impact on the phe-
nomenon under study. In fact, describing the diﬀerences between individuals by
means of covariates is the way heterogeneity between individuals are usually taken
into account in medical statistics and in epidemiology. In general it is not likely
that all relevant covariates can be included in such an analysis. Some covariates
are not included because of practical, ethical or economic reasons, while others are
simply not suspected to have an inﬂuence. This consequently leads to some unob-
served heterogeneity between individuals. What if the ’important’ heterogeneity is
caused by these unobserved covariates? Even if all relevant covariates could have
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been included, there will always be some unexplained rest. Failing to account for
unobserved diﬀerences may be serious.
Accounting for unobserved heterogeneity between individuals has a long his-
tory. In 1959, Beard studied mortality in a population, and introduced a random
eﬀect to model survival data [2]. The term frailty, however, was not introduced
until 1979, by Vaupel et al. [3]. The frailty is considered a random variable
that models the variation in risk between individuals. The individual hazard rate
is deﬁned as the frailty variable multiplied with some basic hazard rate that is
shared by all individuals, but possibly inﬂuenced by covariates. In this way, the
heterogeneity due to observed and unobserved factors are separated.
Several cancers has peaking incidence rate curves with respect to age. In the
interpretation of such an observation, it can be of crucial importance to take into
account possible frailty eﬀects. One straight forward interpretation of the shape of
the incidence curve could be that each individual experiences an increasing risk of
developing the disease up to a certain age, before the risk starts to decline. Taking
the frailty view, on the other hand, the explanation would be that the shape of the
incidence curve is a result of selection eﬀects in the population. While the risk for
each individual is increasing throughout life, there are some individuals with a very
high susceptibility. The highly susceptible, or frail, individuals will develop the
disease early. After some time, the population will contain a smaller and smaller
proportion of highly susceptible individuals, and the incidence rate will drop. The
age-incidence curves of several cancers ﬁt this description, and the incidence curves
of e.g. testicular cancer [4], colorectal cancer [5], nasopharyngeal carcinoma [6] and
Hodgkin lymphoma [7] have all been analyzed from a frailty point of view. Also
the incidence rates of other diseases, like Schizophrenia [8], have been modeled by
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this approach. It is important to note that in such studies, the frailty approach has
biological underpinnings, and is not just a mathematical construct. For cancers,
or other diseases, where some heritable component is thought to be present, frailty
models oﬀers a way of describing the varying genetic disposition to the disease. In
a cancer setting, these models use the knowledge available on the individual level,
trough e.g. a carcinogenic model like the Armitage-Doll model [9], combined with
the notion of a varying susceptibility between individuals, to describe observations
in a population.
In many situations it is not reasonable to assume that individuals are inde-
pendent. For monozygotic twins, for instance, the times to some event are often
associated in some way (e.g. when a disease that has some genetic component
is under consideration). The simplest multivariate frailty model that accounts
for this is the shared frailty model, introduced by Clayton in 1978 [10]. Rather
than letting the frailty be distributed across individuals, the frailty is distributed
across clusters, which could e.g. be pairs of monozygotic twins. However, in many
situations the shared frailty model is not ﬂexible enough, and it might be more
reasonable to let the frailties be correlated rather than shared within the clusters.
If a pair of monozygotic twins have another sibling, it is often the case that the
twins are more correlated than a twin and the other sibling. Several other types of
multivariate frailty models has been proposed to handle such situations. Hougaard
introduced a multiplicative frailty model, where the frailty of an individual was the
product of two independent frailties [11]. One of these frailties would be common
for all siblings, while the twins share another part of the frailty independently of
the ordinary sibling. Another correlated frailty model, uses an additive decompo-
sition of each individuals’ frailty, and diﬀerent parts of the additive components
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are shared between individuals to construct diﬀerent correlation structures. Early
papers introducing this type of models were Pickels et al. in 1994 [12] and Yashin
et al. in 1995 [13].
This thesis considers several aspects of frailty analysis applied in a cancer set-
ting. Paper 1 modiﬁes the Armitage-Doll model with random frailty, to capture
the narrow peaks in the age-incidence curves of osteosarcoma and Ewing sarcoma.
Paper 2 analyzes population wide data on the incidence of testicular germ-cell tu-
mors (TGCTs) in Norwegian families, and we emphasize the calculation of familial
risk of disease. The paper considers a frailty model that randomizes a parameter in
the compound Poisson distribution for individual frailty. The randomized param-
eter is decomposed additively to account for the correlation structure in a family
with up to ﬁve children. In paper 3, the persuasive evidence of the presence
of (unmeasured) inter-individual variation in the risk of cancer, as well as other
diseases, is discussed, and several potentially surprising eﬀects of frailty on stan-
dard epidemiological measures is pointed out. Paper 4 introduces frailty eﬀects
as a possible explanation of the peaks seen in the hazard rates (with respect to
re-occurrence and mortality) after treatment of several cancers, including breast
cancer. A modiﬁed univariate frailty model for modeling bimodal hazard rates is
introduced, and applied to analyze a dataset of breast cancer patients to examine
whether the bimodality of the hazard rate, with respect to mortality, could be
explained by this hypothesis.
Carcinogenic models are often used as a justiﬁcation of the parametric form
of the basic hazard rate in the frailty model, and such carcinogenic models are
discussed in Section 2. In Section 3, the diﬀerent frailty models mentioned in this
introduction are discussed in somewhat more detail, and the hierarchical frailty
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model is introduced [14–17]. Section 4 considers the deﬁnition, and calculation, of
familial risk of diseases. The frailty relative risk (FRR) is introduced. Section 5
gives summaries of the four papers, while a discussion and some ideas for future
work are given in Section 6.
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2 Models of carcinogenesis
Inspired by the work of Nordling [18], Armitage and Doll postulated their famous
model of carcinogenesis in 1954 [9]. Their model stated that a cell had to go
through certain transitions to become malignant. They stressed the fact that
these transitions did not necessarily have to be mutations, and that the actual
nature of the transitions was not important in a mathematical analysis. The basic
observation was that incidence rates of many cancers increased with a certain power
of age, such that a plot of the logarithm of age versus the logarithm of the incidence
rate gave a straight line. Such cancers are often termed log-log cancers. Armitage
and Doll demonstrated this feature for a number of cancers, limited to the age
interval 25-74 years. However, the model did not ﬁt all cancers, especially not
those with a peaking incidence at an early age. In their original article Armitage
and Doll stated that
”The relatively high rates at the younger ages could result if the
population contained a group of subjects specially susceptible to cancer
(...)”.
After the Armitage-Doll model was ﬁrst published, other models have been
proposed. The Moolgavkar-Knudson model considered two mutations [19]; ﬁrst a
transformation from a normal cell to an intermediate cell, followed by a period of
clonal expansion, culminating in a mutation of an intermediate (daughter) cell to
a malignant cell. Various shapes of population incidence rates were explained by a
varying number of available susceptible stem cells, and a peaking age-incidence rate
were explained by the exhaustion of susceptible stem cells within each individual.
Several modiﬁcations of the model have been made [20–23], including allowing for
more than two mutations [20].
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Even though it is simple, the Armitage-Doll model continues to play a funda-
mental role in the theory of carcinogenesis. Combined with a proper treatment
of the unobserved heterogeneity between individuals, the Armitage-Doll model is
able to capture also the peaking incidence rate of cancers [4, 5, 8], which is what
Armitage and Doll foresaw in the above given quote. Rather than the exhaustion
of susceptible stem cells, the heterogeneity, in the susceptibility to the disease,
between individuals is considered as a possible explanation of a peaking incidence
curve.
Throughout this thesis, and in the papers that comprise it, we consider an
individual hazard rate as the product of a basic hazard rate and a random variable
that describes the frailty of the individual. In papers 1-3, the basic hazard rate
is assumed to increase with some power of age, which corresponds to a Weibull
form, and the Armitage-Doll model is used as the justiﬁcation. However, other
approaches also give rise to a Weibull form of the basic hazard rate [24, 25]. In fact,
the Weibull model is the most commonly used parametric model for carcinogenesis
[25].
3 Frailty models
This section gives an overview of the models that form the starting points for
methods developed and used in the papers in this thesis. However, all types of
frailty models are not considered here, and the reader is referred to one of the
books of the ﬁeld for a complete overview [26–30].
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3.1 The proportional frailty model
In the proportional frailty model the hazard rate of an individual is given as a
basic hazard rate, λ(t), multiplied with a quantity, Z, that expresses the extent of
frailty in the individual (see e.g. chapter 6 in Aalen et al. [28]),
α(t|Z) = Zλ(t), (1)
where t is the time from some starting point (typically, t is age). The frailty,
Z, is considered a random variable over the population. The individual survival
function is given by
S(t|Z) = exp(−ZΛ(t)),
where Λ(t) =
∫
λ(t)dt. The population survival function is found by integrating
out the frailty variable in the individual survival function,
S(t) = E[exp(−ZΛ(t))] =
∫
exp(−zΛ(t))f(z)dz,
where E denotes expectation, and f is the distribution function of Z. Since the
Laplace transform of the distribution function of Z is given by
L (c) = E[exp(−cZ)] =
∫
exp(−cz)f(z)dz,
the population survival function can be expressed as S(t) = L (Λ(t)). The popu-
lation hazard rate is then found as
μ(t) = λ(t)
−L ′(Λ)
L (Λ)
.
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As mentioned above, a Weibull form of the basic hazard rate is usually assumed,
λ(t) = katk−1, k > 0,
where a is a scale parameter. When studying cancer incidence, this is justiﬁed by
carcinogenic models [9, 25], and k is interpreted as the number of events necessary
for a cell to become malignant [4]. Thus, k > 1 is a more realistic interval for k
[4]. The model combines the available information on the individual level, from
the carcinogenic model, with what is actually observed in the population. The risk
of having an event (i.e. cancer) will increase throughout life. The most frail, or
susceptible, individuals are likely to have an event early, causing the population
hazard rate to rise. With time, there will be a decreasing proportion of highly
susceptible individuals left in the population, and the population hazard rate will
decrease. In paper 1, the proportional frailty model (with Weibull basic hazard
rate) is referred to as The Armitage-Doll model with random frailty.
3.2 Frailty distributions
The most commonly used frailty distribution is the gamma distribution [28].
Hougaard presented the power variance function (PVF) family of distribution
that includes both the gamma distribution and several other distributions as spe-
cial cases [26, 31]. Aalen showed that the compound Poisson (cP) distribution is
also included in this class of distributions [32]. The cP distribution may be deﬁned
as the sum of N independent gamma distributed variables, each with scale param-
eter ν and scale parameter η, where N is Poisson distributed with expectation ξ.
The papers in this thesis considers the gamma and the cP distributions only. The
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Laplace transforms are given as
LcP (c) = exp
(
−ξ
(
1−
(
ν
ν + c
)η))
, (2)
where and ξ, ν and η are all > 0, and
Lgamma(c) = exp (−δ (log (θ + c)− log (θ))) ,
where the shape parameter, δ, and the scale parameter, θ, are both > 0. However,
the PVF distributions are part of a broader class of distribution, namely the Le´vy-
type distributions. Consider the Laplace transform
L (c) = exp(−sφ(c)), (3)
where s is a non-negative parameter and φ(c) is called a Laplace exponent, and has
a parametric form depending on the frailty distribution. This is a valid Laplace
transform for all Le´vy-type distributions [28, 33]. For the cP, and the gamma
distribution, the Laplace exponents are given as
φcP (c) = ξ
(
1−
(
ν
ν + c
)η)
, ξ > 0
and
φgamma(c) = δ (log (θ + c)− log (θ)) . (4)
However, for the cP distribution, s is usually subsumed in the ξ parameter, or,
equivalently, the re-parameterization ρ = sξ is used, and the Laplace transform
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and the Laplace exponent are consequently frequently written as
LcP (c) = exp(−ρφcP (c))
and
φcP (c) = 1−
(
ν
ν + c
)η
,
respectively [28], yielding the Laplace transform in (2), with ρ considered the
expectation of the underlying Poisson variable. A similar re-parameterization may
be done for the gamma distribution. However, it can be useful to keep the s
parameter explicit, especially in the formulation of the hierarchical frailty model
(Section 3.6), as done by Moger et al. [17].
3.3 Modeling bimodal hazard rates
Several cancers, and other diseases, exhibits incidence rates with more than one
peak. Taking frailty into account may be of crucial importance in these instances.
For nasopharyngeal carcinoma, Haugen et al. proposed a method for modeling the
two peaks seen in the incidence rate [6]. They modeled the individual hazard rate
as a linear combination of two independent frailties,
α(t|Z1, Z2) = Z1λ1(t) + Z2λ2(t).
The ﬁrst frailty, Z1 represented the risk due to unobserved ”genetic and viral
factors”, while Z2 represented risk due to unobserved lifestyle factors. Both λ1
and λ2 were assumed to have a Weibull form, and the population hazard rate was
found by the same approach as in Section 3.1. The model has also been used
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for modeling the bimodal hazard rate of Hodgkin lymphoma [7]. In both these
applications [6, 7], data from large registries with many events were analyzed.
However, it is well known that the estimation of frailty models from single event
data may be accompanied by a high degree of uncertainty [28]. For situations where
less data are available, this could pose a problem. Furthermore, it can be hard to
justify the separation of the unobserved heterogeneity into two diﬀerent sources.
In paper 4, a simpler model for modeling bimodal hazard rates is proposed, where
the individual hazard rate is given as
α(t|Z) = Z (λ1(t) + λ2(t)) .
The frailty acts multiplicatively on the sum of two basic hazard rates. The basic
idea is that there are two distinct underlying biological processes that are both,
over time, increasing the individual risk of having an event. One of these may, for
instance, be increasing steadily from some deﬁned starting point, while the other
process might be increasing much more slowly in the beginning of the period under
study, and then increase more rapidly and at some point begin to dominate the
sum of the two hazards. In that case, it would mean that the frailest individuals
are likely to have an event related to the ﬁrst hazard, while only the strongest
(least frail) will in practice be inﬂuenced by the second process. This would lead
to a bimodal shape of the population hazard rate. In paper 4, where survival after
conservative breast cancer treatment is studied, it is hard to justify the separation
of the unobserved heterogeneity in the same way as by Haugen et al. [6]. Especially
considering the relatively short time span in our study (∼ 10 years of follow-up).
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3.4 Shared frailty models
In the proportional frailty model (Section 3.1), Z expresses the level of frailty in
an individual. However, in many situations it is likely that some survival times are
related to each other. Organs within the same individual, or units in a hospital
are examples. As mentioned in the Introduction, it is, for a genetic disease, often
the case that two monozygotic twins have a similar predisposition for attaining
the disease (beyond what is modiﬁed by possible measured environmental risk
factors). One way of accounting for this is to let the twins share the same value
of the frailty.
The shared frailty model takes the same form as the proportional frailty model,
but the frailty is distributed over clusters (e.g. families) rather than individual
entities (persons). The proportional frailty model is thus a special case of the
shared frailty model, with cluster size one. The shared frailty model is discussed
at great length in the books by Hougaard [26] and Duchateau and Janssen [27].
While we are interested in the distribution of the frailty in the univariate (i.e.
proportional) frailty model, it is possible to estimate the level of frailty in each
cluster from the shared frailty model using an empirical Bayes approach (see e.g.
Aalen et al. chapter 7 [28]).
3.5 Additive frailty models
Letting each member of a cluster share the same value of the frailty may be too
simplistic. In a multi-center trial, it is for instance possible that hospitals that
are geographically closer to each other might be more correlated than those fur-
ther apart. Diﬀerent units within hospitals may have diﬀerent frailties, but are
likely to be correlated to some degree. Diﬀerent members of a family will most
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certainly have some correlation, but it is for instance obvious that a father and a
son is more correlated than a father and a mother, if a disease with some genetic
component is under consideration. Additive frailty models are constructed to take
these aspects, i.e. correlation structures within clusters, into account, and are
therefore frequently referred to as correlated frailty models (although correlated
frailty models is a broader class of models, where the frailty of an individual is not
necessarily decomposed additively).
Yashin et al. considered a frailty model where a sum of several frailty variables
acted multiplicatively on the basic hazard rate [13]. They noted that in twin
studies, the frailty should be correlated rather than shared, to e.g. be able to
include both monozygotic and dizygotic twins. They considered three independent
gamma distributed variables, Y0, Y1 and Y2. The frailty of the twins was expressed
as Z1 = Y0 + Y1 and Z2 = Y0 + Y2, respectively. In fact, studies of twins is the
most frequent application in papers developing and/or applying additive frailty
models [12, 13, 34–40]. The model can, however, easily be extended to model
other correlation structures [41, 42]. Several types of correlated frailty models are
thoroughly discussed in the book by Wienke [29].
Korsgaard and Andersen gave several examples of what they have named ad-
ditive genetic frailty models [41]. Their simplest example considered a family of a
mother, a father and a child. They considered four identically, independently dis-
tributed gamma(λ/2, λ) random variables, Y1, Y2, Y3 and Y4. Here, ZF = Y1 + Y2,
ZM = Y3 + Y4 and ZC = Y1 + Y3 represented the additively decomposed frailties
of the father, mother and the child, respectively. Thus, Y1 and Y3 was the parts
of the parents’ genes aﬀecting the frailty transmitted to the child. There was no
correlation between the frailty of the parents, whereas the child and each parent
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had correlation 1/2. This simple model forms the basis of the familial correlation
structure used in paper 2.
3.6 Hierarchical frailty models
A hierarchical frailty model is a useful combination of the models described in
Sections 3.1, 3.4 and 3.5. Let the distribution function of the frailty variable Z1
have Laplace transform
LZ1(c) = E[exp(−cZ1)] =
∫
exp(−cz1)fZ1(z1)dz1 = exp(−z2φ1(c)), (5)
where E denotes expectation and fZ1 denotes the distribution function of Z1.
The parametric form of the Laplace exponent φ1 depends on the choice of frailty
distribution, and z2 is a constant parameter. The population survival function is
S(t) = LZ1(Λ(t)), as in Section 3.1.
Let now the parameter z2 be randomized by Z2, which has Laplace transform
LZ2(c) = exp(−z3φ2(c)),
where φ2 depends on the distribution of Z2, and z3 is a non-negative constant
parameter. The marginal Laplace transform for the combined frailty of each indi-
vidual is then given by
L (c) = E[exp(−Z2φ1(c)] =
∫
exp(−z2φ1(c))fZ2(z2)dz2 = exp(−z3φ2(φ1(c))),
where fZ2 is the distribution function of Z2. Similarly, we could add another level
in the model, by randomizing z3 by Z3, whose distribution function has the Laplace
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transformLZ3(c) = exp(−z4φ3(c)). The Laplace transform of the combined frailty
of an individual would then be
L (c) = E[exp(−Z3φ2(φ1(c)))] = exp(−z4φ3(φ2(φ1(c)))).
If even further levels are needed, one could continue by randomizing z4, and so
on. The ﬁrst level could represent the frailty variation between individuals, as in
the proportional frailty model, the second level could represent the frailty that
varies between families (but are shared within families). The third level could e.g.
represent frailty variation between neighborhoods and so on. However, in paper
2 we have two levels only.
As discussed in Section 3.2, the parameter zi+1 in the Laplace transform for
the variable Zi, can be viewed directly as a parameter in the distribution of Zi
[14–16], or as a scale transformation of that parameter [17]. If Zi is cP distributed,
and
φi(c) = 1−
(
ν
ν + c
)η
,
then the parameter zi+1 is equivalent the underlying Poisson parameter in the
cP distribution. This parameterization is used for the cP distributed ﬁrst-level
frailty in paper 2. For the gamma distribution, the parameterization given in
expressions (3) and (4) is used in paper 2. That is, zi+1 is viewed as a scale
transformation of a parameter in the frailty distribution. However, since no more
levels were added, zi+1 = 1 in that case (and hence there is no diﬀerence between
the two parameterizations of Section 3.2).
Hierarchical frailty models have been developed in recent years [14–16], and
does not ﬁt in the same group as other classes of multivariate frailty models (e.g.
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additive). Interpretation-wise, letting the ﬁrst-level frailty be cP distributed is
very interesting. Randomizing z2 allows the members of diﬀerent families to have
diﬀerent probabilities of having zero frailty. Given z2, the individuals in a family
are independent. Although members of a family shares the value of z2, the model
e.g. allows for two members of a family were one has zero frailty, while the other
could have a positive frailty.
It does not always make sense that all the family members have the same
second-level frailty. Moger et al. proposed to decompose a level in the hierarchical
frailty model, to impose a certain correlation structure in the family [17]. They
used the same approach as Korsgaard and Andersen [41], although allowing for
two children in a family. Furthermore, they had three levels in their model; the
ﬁrst one described the varying individual frailty, the second level described the
correlation structure of a family in an genetic additive fashion as described by
Korsgaard and Andersen, and the third level described a frailty shared among the
family members due to environmental factors. The frailties on all levels (and in
the additive decomposition) were gamma distributed, with the expectation on each
level set to one. A consequence is that they were able to estimate the parameter
of the third-level frailty due to the correlation between the parents in the family.
As mentioned above, the model in paper 2 has two levels only; the individual
variation in frailty on the ﬁrst level, and the familial frailty variation on the second
level. The model allows for up to ﬁve children, and decomposes the genetic second-
level frailty into 16 components, as opposed to two in Korsgaard and Andersen
[41], and four in Moger et al. [17]. Since females are not considered, adding
another level, to serve as a shared environment term is not feasible. However, we
add a term accounting for the environment shared among brothers independently
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of their fathers, inspired by the work on additive models [41, 42]. In this way
it is ensured that the correlation is larger between brothers than between father
and son. Furthermore, the model in paper 2 uses a cP distributed ﬁrst-level
frailty, that opens up for interesting interpretational aspects. The randomized z2
parameter is correlated rather than shared between individuals in a family. This
means that two individuals does not need to have the same probability of having
zero frailty, although the probabilities are correlated.
4 Familial Risk
There are several cancers that shows some degree of familial clustering. Such a
clustering naturally leads us to think that there are some heritable aspects involved
in the development of the cancer. Families usually share a very similar environ-
ment, and environmental risk factors could also play a role in familial clustering.
However, as discussed in paper 3, such risk factors are not likely to be the main
drivers of familial risk [43, 44]. In any case, familial risk is something that both
patients and their families might be concerned with, and it is something that even
show up in the general media form time to time. It is therefore of great interest
how such risks are estimated.
Familial risks are usually considered as the risk of developing the disease in
question if a family member is aﬀected, and compare that risk to the general risk
level in the population. It is not obvious how to give such an estimate, especially
for siblings, and there are several diﬀerent approaches. One option is to have an
index case in each family (the proband), and to compare the incidence rate in
family members of these index cases to the incidence rate in the population [45].
Another approach is to let the ﬁrst individual in the family who has an event be
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the index case, and to let the family members be a part of the risk set from the
time of the index case had the event [46].
Usually, estimation of familial risk is based on data from population wide reg-
istries. Over the last decade or so, the most dominant approach for providing
estimates for sibling risks is the cohort method given by Hemminki et al. [47]. As
mentioned in paper 2, it is not entirely clear how these calculations are done,
because there appears to be an error in the formula in Hemminki et al. [47] (see
paper 2). The paper is nevertheless heavily cited (see selected references in pa-
per 2), and the formula is even reproduced with the same error elsewhere [48, 49].
However, the approach seems to be to pool all siblings with at least one aﬀected
sibling into one big cohort, and ﬁnd the standardized incidence ratios (SIRs) by
comparing the incidence rate in this cohort to that of the general population. This
means that in a group of siblings with more than one aﬀected individual, all in-
dividuals give a contribution to this deﬁned cohort. It is not intuitively easy to
understand the rationale behind the formula, and it needs better justiﬁcation. In
any case, although useful, the SIR approach provides merely summary measures.
4.1 Frailty relative risk (FRR)
The large population wide registries in the Nordic countries provides, because of
the possible linkage trough the personal identiﬁcation number, unique opportuni-
ties to study familial diseases. More advanced analyses of the complex data that
are available could provide much more information than analyses giving summary
measures. Hierarchical (and additive) frailty models can be very useful in this
regard.
Consider two members of the same family, individuals A and B. Moger and
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Aalen proposed a frailty relative risk (FRR) to express the familial association of
a disease [15, 16],
FRR =
P(A has disease within time tA|Family member B has disease within time tB)
P(A has disease within time tA|Family member B has not had disease within time tB)
. (6)
The fact that given all higher level frailties any pair of individuals are independent,
the FRR can be expressed trough the Laplace transforms of the frailty variables.
The relative risk in (6) resembles a traditional relative risk, comparing two ex-
clusive groups. In studies of familial risk, however, the comparison of interest is
usually the general risk level in the population. With this in mind, the FRR in
paper 2 is deﬁned as
FRR =
P(A has disease within time tA|Family member B has disease within time tB)
P(A has disease within time tA)
, (7)
which is actually the same as the deﬁnition originally given by Moger et al. [14].
The FRR may be expanded to include more members in the family that develops
disease or not within speciﬁed ages. In Web Appendix 4 of paper 2 the FRRs for
certain constellations are expressed in terms of the survival functions. However,
the FRR may easily be calculated for any constellation. Also, the FRR can be
deﬁned to condition on the exact timing of when the family member developed
then disease. The FRR would then be expressed in terms of the derivative of the
survival function.
The FRR allows for great ﬂexibility with regards to the structures and the
sizes of the families, and enables us to be very precise in our deﬁnition of familial
risks. The ease of which the relative risk given multiple aﬀected and/or unaﬀected
family members are found, once the model parameters have been estimated, is
particularly appealing. As of now, the hierarchical frailty model is somewhat
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computing intensive, and one advantage of the SIR approach is that it is easy to
calculate.
5 Summary of papers
5.1 Paper 1
Frailty modeling of age-incidence curves of osteosarcoma and Ewing sarcoma among
individuals younger than 40 years.
The Armitage-Doll model with random frailty (i.e the proportional frailty model
with Weibull basic hazard rate) model the incidence rate of several cancers well
[4–6]. In this paper it is demonstrated that this model is not able to capture
the very steeply increasing, and later plummeting, incidence rates of the bone
cancers osteosarcoma and Ewing’s sarcoma. This is the case even if the cP frailty
distribution is used. The peaks in the incidence rates of the two cancers coincides
with the growth spurt period in adolescence, a period where the host tissue (i.e.
bone) is expanding. A model that takes into account a biological mechanism that
is accelerated at some, possibly short, period of life, is presented. The model ﬁt
the incidence curves of osteosarcoma and Ewing’s sarcoma well when growth is
seen as the accelerated process, and the results support evidence for an underlying
susceptibility for these diseases. It is indicated that (susceptible) individuals with
an unusually rapid growth spurt may develop the diseases earlier than they would
have if their growth spurts had been closer to the average. This could lead to an
excess incidence early in puberty, followed by a compensation leading to a faster
decrease of the incidence rate than would have been expected if growth spurts were
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more similar across individuals.
5.2 Paper 2
A hierarchical frailty model for familial testicular germ-cell tumors.
We analyzed incidence data on testicular germ-cell tumors (TGCT) in all Norwe-
gian families registered since the personal identiﬁcation number was introduced in
1960, obtained trough a linkage between Statistics Norway and the Cancer Reg-
istry of Norway. A total of 1,135,320 families were included, and 7,524 families
had at least one member aﬀected by TGCT.
Moger et al. developed a hierarchical frailty model where the frailty on a certain
level were decomposed in an additive fashion to take the correlation structures
within families into account [17]. We modiﬁed the model to analyze a male cancer
that is also, possibly, inﬂuenced by a maternal mode of inheritance. Furthermore,
we expanded the model to take into account more children in a family, and we let
the correlation between brothers be larger than the correlation between father and
son.
The paper highlighted how the FRR provides accurate deﬁnitions of familial
risks, and the ﬂexibility of the FRR as a measure of familial association. This was
demonstrated by its calculation given multiple aﬀected or healthy family members.
Given one aﬀected brother, the lifetime FRR was 5.88 (95% conﬁdence interval
(CI): 4.70, 7.36). Given two aﬀected brothers, the FRR was 21.71 (95% CI: 8.93,
52.76), and if there were two additional healthy brothers in the family, the FRR
was 15.80 (95% CI: 9.56, 26.11). A borderline signiﬁcantly higher FRR for non-
seminoma than for seminoma (P =0.06), the two main histological subtypes of
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TGCT, were found for sons of aﬀected fathers.
Several of the diﬀerent FRRs estimated in the paper (those who took multiple
diseased and/or healthy siblings into account), have not previously been reported
for TGCT.
5.3 Paper 3
Understanding variation in disease risk: the elusive concept of frailty.
The paper pointed out how variation in risk that goes beyond measured risk factors
are present. It gave examples of how variation in risk of cancers, and other diseases,
may be established early in life, or even prior to birth. It was discussed that much
of this variation may be due to randomness. Also, it was discussed how even
moderate familial risks are indications of very large individual variations in risk
of disease. Furthermore, a number of consequences of frailty on fairly standard
epidemiological measures were pointed out. This included peaking age-incidence
curves, as in paper 1, and also how frailty may aﬀect incidence rates over calendar
time. It was also discussed how frailty may play an important role when comparing
hazard rates of diﬀerent groups in e.g. a clinical trial. The paper stressed that
observations in a population may be totally unrepresentative for the individual,
and the biological processes within. In many situations the presence of unobserved
heterogeneity cannot be ignored.
5.4 Paper 4
Investigating tumor dormancy with frailty models.
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Several cancers show peaking hazard rates with respect to re-occurrence and, even-
tually, death, after treatment of the original tumor [50, 51]. The peak in the hazard
rate may be found a long time after the initial treatment. For some cancers, several
peaks have been observed, and the latest peak have occurred many years after ini-
tial treatment. This phenomenon is usually explained by tumor dormancy, which
means that malignant cells or micrometastases remains non-proliferative a long
time after treatment. We studied overall survival in a dataset from the Milan Na-
tional Cancer Institute, consisting of 1657 breast cancer patients having received
conservative surgery followed by radiotherapy.
A frailty model for capturing bimodal hazard rates was proposed. The model
was simpler than previously suggested models [6, 7], in the sense that only one
frailty variable was introduced in the model. The model took on the form of a
proportional frailty model, but the frailty variable was multiplied with the sum
of two basic hazard rates. The two basic hazard rates represented the two main
micrometastatic processes, i.e. originating from single dormant cells or from dor-
mant micrometastases, and were both assumed to have a Weibull form. The model
captured the two peaks in the hazard rate, and the paper set forth the hypothesis
that this behavior could be, at least in part, due to a selection phenomenon. Al-
though it is clear that other models based on diﬀerent assumptions might ﬁt the
date equally well (or even better), the paper oﬀered a new view on the bimodality
of the hazard rates (with respect to death) following treatment of breast cancer.
6 Discussion
As the title of this thesis suggests, the aim has been to elucidate the presence, and
importance, of unobserved individual diﬀerences in cancer. The term cancer is,
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of course, very broad, and includes over 100 diseases that may arise from almost
any cell type in the body [52]. Even though they have some common features,
it is challenging to make general statements about such a large range of diseases.
Nevertheless, it makes intuitively sense that the development of any disease is
subject to individual diﬀerences beyond the ones that are known to have an eﬀect.
Paper 3 focuses on pointing out the evidence for large variation in individual risk,
and demonstrates, using only hypothetical examples, some possible implications
of this variation on epidemiological measures. Papers 1, 2 and 4 focuses on
speciﬁc cancer types. These three papers all have some degree of methodological
development, and an applied side. When univariate frailty models are applied to
data, there is always some speculative elements involved. Both paper 1 and paper
4 are no exceptions in that regard, and paper 4 is perhaps the most speculative.
However, the assumptions made are reasonable from a biological point of view in
both papers. When clustered data is analyzed, the degree of speculation is reduced
[28], and Paper 2 is, perhaps, the most interesting from both a methodological
and applied standpoint.
The contribution of paper 1 is the modiﬁcation of the Armitage-Doll model
with random frailty, to account for an accelerated biological process in the host
tissue of the cancer, at some point in time. One (at least implicit) criticism
of the Armitage-Doll model as such, has been that it is not able to take into
account an expanding host tissue [19]. Paper 1 shows that this is the case even
when frailty is accounted for. However, a consequence of the paper is that the
Armitage-Doll model may easily be modiﬁed to take this into account, which
was also mentioned in paper 3. The proposed model ﬁts the incidence data of
osteosarcoma and Ewing’s sarcoma well, and another contribution of paper 1
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is thus to act as supporting evidence for an underlying predisposition for these
cancers. Possible extensions of this work would be to include data from several
sources. Since obesity may inﬂuence both the timing of puberty and the velocity
of growth in adolescence [53], it would be of great intresest to analyze data from
countries at diﬀerent stages of the so-called obesity epidemic. Furthermore, the
model could possibly be improved by letting the timing of the onset and end of the
period of enhancement of the biological process be distributed according to some
distribution, rather than being ﬁxed quantities.
A contribution of paper 2 is the development of a hierarchical frailty model
that takes familial correlation into account, for a disease that only males can de-
velop, but that has a possible maternal mode of inheritance. Furthermore, the
model allows for a correlation that are diﬀerent for siblings than for parent-child
pairs (as opposed to the study by Moger er al. [17]), as well as allowing for more
children per family. The paper demonstrates how, once the parameters of the
model has been estimated, the familial risk given virtually any combination of
healthy/diseased family members may be found. Of special interest is the 21-fold
increased risk of developing TGCT if two brothers have had the disease, and how
this estimate is aﬀected by additional, healthy brothers. Such estimates have,
to our knowledge, not previously been published for TGCT. Although this study
was the ﬁrst analyzing data from a complete national registry using this type of
methodology, it would be very interesting to be able to combine data from all (or
some) of the Nordic countries. In this way, more precise estimates for the relative
risks considering multiple aﬀected family members could be obtained. Further-
more, it would be useful to have a ready-made computer program for estimating
this type of models. Although estimation of the model used in paper 2 was some
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computer intensive, this could be feasible by implementing the program in a faster,
lower-level programming language than R.
The contributions of paper 3 are related to the illustrations of the existence
of frailty eﬀects in many aspects of biology and in the development of cancers and
others diseases. The paper discusses how artefacts due to frailty, well known from
survival analysis, may be of crucial importance for correctly interpreting fairly
standard epidemiological measures. Thus, the paper contains both justiﬁcations
of the importance of a frailty approach in analyzing data in various situations,
as well as communicating to a non-statistical audience that frailty variation is
important for correct interpretation.
The main contribution of paper 4 is that it generates the hypothesis that
the bimodal mortality rate after treatment of breast cancer patients is, in part,
due to selection (i.e. frailty) eﬀects. A univariate frailty model for capturing
bimodal hazard rates is developed, and used to estimate the population hazard
rate with respect to mortality in breast cancer patients receiving conservative
treatment. The knowledge of the mechanisms that control what is referred to as
tumor dormancy is limited, and the eﬀects of the included covariates may thus
be useful with regards to which patients that should be followed up most closely.
With regards to further work, it would be interesting to apply the model to a even
larger dataset, to obtain more precise results. Furthermore, a dataset (of breast
cancer or other, relevant types of cancer) with longer follow-up could allow for the
model to be expanded to include another basic hazard rate, possibly capturing
another peak (if present). Also, it could be interesting to study the causes of
death, and to apply a competing risks model where the cause-speciﬁc hazard rates
could take on the form of the proposed model, with possibly correlated frailties.
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Abstract: 
Background 
The concept of frailty plays a major role in the statistical field of survival analysis. Frailty 
variation refers to differences in risk between individuals which goes beyond known or 
measured risk factors. In other words, frailty variation is unobserved heterogeneity. Although 
understanding frailty is of interest in its own right,  the literature on survival analysis has 
demonstrated that frailty effects can lead to surprising artefacts in statistical estimation that 
are important to examine.  
Methods 
We present literature that demonstrates the presence and significance of frailty variation. We 
discuss the practical content of frailty, and show the link between frailty and biological 
concepts like (epi)genetics and heterogeneity in disease risk. 
Results 
Evidence is pointed out for the pervasive presence of heterogeneity between individuals. 
There are numerous suggestions in the literature that a good deal of this variation may be due 
to randomness. Heterogeneity often manifests itself as clustering of cases in families. We 
emphasize that apparently moderate familial relative risks can only be explained by strong 
familial variation. Finally, we highlight the potential impact of frailty on standard 
epidemiological measures. 
Conclusions 
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Frailty variation is normally present and a good understanding of this phenomenon may be 
important in order to correctly interpret statistical analyses in epidemiological studies. Even 
moderate familial risk points to a high degree of variation between families and individuals. 
Statistical artefacts may arise as the result of frailty variation in many settings, and one should 
be cautious in the interpretation of hazard and incidence rates. 
Keywords:  Frailty, heterogeneity, random variation, epigenetics 
Key messages: 
x Variation in risk of disease often goes far beyond what is captured by measured risk 
factors.  
x Much of the heterogeneity in risk may be established early in life, and stochastic 
variation in these processes could be a major contributor in this regard.  
x Even moderate familial risk points to the existence of large variations in risk between 
families, and individuals, in the population.  
x Failing to take into account the unobserved heterogeneity between individuals may 
lead to erroneous interpretations of standard epidemiological measures, like hazard 
ratios and age-incidence curves.
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Introduction 
In epidemiology and clinical science, it is often tacitly assumed that the risk of individuals 
with respect to a certain disease is similar in a population, apart from well documented 
differences due to risk factors or genetics. It is often presumed, for instance, that all 
individuals are vulnerable to the same risk factors. Differences between individuals tend to be 
ignored unless they can be expressed in terms of known risk factors or known genetic 
properties. However, the fact of the matter is that individuals are generally highly dissimilar 
also for a number of unknown, or just partly known, reasons. Indeed, the extent of this 
heterogeneity is probably not generally appreciated. 
 
Heterogeneity which is unknown, or not represented in available data, is often referred to as 
frailty, a quantity that is varying between individuals. The term frailty comes from the 
statistical field of survival analysis, where there is a strong interest in this type of 
heterogeneity. Frailty is usually modeled by assuming that the hazard rate (baseline hazard) 
for an “average individual” is multiplied by a factor Z that renders the level for a specific 
individual: 
ߣሺݐሻ ൌ ܼߙሺݐሻ 
When we integrate out the variation in Z to get the (observable) population hazard rate, the 
resultant function is quite different from the baseline hazard D(t). A number of various 
distributions exists for the frailty Z.1, 2 Note that the baseline hazard may be a function of 
observed individual covariates, e.g. through a Cox model. 
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A number of diseases exhibit  incidence rates that peak at young ages, including cancers like 
childhood leukemia and Hodgkin lymphoma, but also schizophrenia, which has recently been 
analyzed from a frailty point of view.3 In several cases frailty variation is a reasonable 
explanation for an early peak in incidence, especially when the disease has a strong 
heritability, which is the case for diseases like schizophrenia and testicular cancer. The frailty 
approach has yielded particularly fruitful insights for testicular cancer.4-7 Furthermore, the so-
called frailty models form a basis for the analysis of familial association in cancer incidence.6-
8 
One goal of the present paper is to point out the ubiquity of heterogeneity, or varying frailty. 
We shall also emphasize the role of stochasticity. Furthermore, we will discuss how important 
indications of frailty variation may be deduced from data on familial association. Indeed, 
moderate familial association implies surprisingly strong variation in risk between individual 
families. Although understanding frailty variation is important in its own right, it may also be 
essential in order to correctly interpret statistical analyses in epidemiological studies. Finally, 
we will cover an issue that has been pointed out in the statistical literature: that unobserved 
frailty variation may lead to misleading comparisons of hazard rates and incidence rates, 
resulting in, among other things, an artificial cross-over effect. 
 
Heterogeneity between individuals may be high 
Individual variation in susceptibility 
It is often obvious that disease risk is a fluid phenomenon, dependent on risk factors, genes, 
and the country of residence, among other things. For example, the risk of colon cancer varies 
widely across different countries; it has increased sharply (in fact more than tripled) in the last 
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few decades in many industrialized countries, and it varies substantially between different 
countries worldwide. This means that the risk of colon cancer is not a given quantity, but 
rather something that varies widely. It would follow that the individual risk of colon cancer is 
also a fluid phenomenon; that it varies considerably between individuals even when the outer 
circumstances are similar. Furthermore, there are large differences in risk across regions 
(Figure 1).9 Therefore, it seems logical that the risk will not be homogeneous within regions 
(especially given the arbitrariness of many borders). In short, the variation in risk between 
regions strongly suggests a considerable variation within regions. This kind of variation has 
been clearly demonstrated for the United States with regard to the dependence on race of 
colorectal cancer incidence.10 However, it is highly likely that there are other variations based 
on unknown risk factors. 
 
Some  of the biomedical literature has indicated that there is a high degree of variation in 
individual cancer susceptibility, thereby supporting the presence of frailty variation. An 
interesting paper is Balmain et al.11 where they indicate a strong variation in susceptibility to 
breast cancer. They studied a population without high-risk individuals (those with BRCA1 
and BRCA2 mutations), and still suggest a 40-fold difference in the risk of breast cancer 
between the top 20% and bottom 20% of the study population. Their model also suggests that 
more than 50% of cancers occur in the 12% of the population that is most susceptible. Peto 
and Mack12 reached similar conclusions by studying the relatives of breast cancer patients. 
They observed a very strong familial risk in monozygotic twins which could only be 
explained by a large individual variation in risk. They make the following statement: “Our 
most surprising conclusion is that a high proportion of all breast cancers, and perhaps the 
majority, arise in women at very high risk.” Also, the increased risk of a second breast 
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malignancy after ductal carcinoma in situ of the breast, even after adjustment for type of 
treatment, points to a large variation between individuals in susceptibility to this disease.13 
 
Regarding colorectal cancer (CRC), Win et al.14 suggest that “the risk of developing CRC 
varies approximately 20-fold between the people in the lowest quartile (average 1.25% 
lifetime risk of CRC) versus the highest quartile for familial risk profile (average 25% risk)”. 
Another study of colorectal cancer in DNA mismatch repair gene mutation carriers showed a 
U-formed distribution in risk distinguishing a high-risk group from a moderate risk-group.15  
 
It is important to be aware that even for cancers with strong attributable risk factors, frailty 
remains a large component. In lung cancer, for instance, there are strong indications that some 
people are much more vulnerable to the damage inflicted by smoking than others; with just 
10-15% of smokers developing lung cancer.16 
 
Susceptibility may be established early in life 
The notion of “early life programming” has become popular. This idea was formulated in the 
Forsdahl-Barker hypothesis, which states that the risk of many diseases is strongly influenced 
by what happens very early in life, e.g. at or prior to birth. Forsdahl17 showed a strong 
correlation between mortality rates for arteriosclerotic heart disease in people aged 40-69 
years, and infant mortality in the same birth cohorts within Norwegian counties.  Earlier 
works include Ravelli et al,18 who observed babies born to women who were pregnant during 
the Dutch famine. They found that the weight of these children later in life depended on 
which trimester the famine affected. Kermack et al. found an association between childhood 
8 
 
and adult mortality for different birth cohorts.19, 20 Barker et al. studied heart disease and 
found that areas in England that had the highest coronary heart disease mortality in the 1980s 
also had the highest child mortality rates 70 years earlier.21, 22 Since then, many papers have 
been published indicating a relationship between early life conditions and disease risk later in 
life,23 including the recent paper by Eriksson et al.24 who assert in the title that “Boys live 
dangerously in the womb”.  
 
Epigenetics is used to describe heritable changes in gene expression that are not caused by 
alterations in the nucleotide sequence of the genome, and Forsdahl- Barker type effects have 
been tied to such epigenetic alterations.25, 26 Painter et al showed that the children of those 
exposed to the Dutch famine in utero during World War II (WWII) were also at increased risk 
for ill health, which indicates that epigenetic effects in utero can even have transgenerational 
consequences.27 Studies from the Netherlands and Scandinavia have shown a decreased risk 
of testicular cancer for birth cohorts born during WWII compared to those born before and 
after.28, 29  
 
All these examples show that epigenetic alterations early in life may lead to a large degree of 
heterogeneity between adult individuals in a population.  
 
Different types of variation 
Figure 2 illustrates various ways in which risk can be distributed between individuals. Panel 1 
indicates a risk that is quite similar across individuals, with some variation. Panel 2 shows a 
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situation where most individuals have a relatively similar risk, but there are some individuals 
who deviate quite a lot (the upper tail). This is expressed even more clearly in panel 3, where 
many individuals have a risk close to zero, while there are a number of individuals with high 
risk. An even stronger variation is illustrated in panel 4, where most individuals have risk 
close to zero, while some individuals have a very high risk. All these types of variation could 
actually occur. The examples given in this paper show that even the types of variation shown 
in panels 3 and 4 could be common. However, another issue is how risk develops over time. 
One view is that there is a rather small variation in risk at an early age, which increases over 
time as the result of the varying stresses of life. An alternative view argues that much of the 
variation in risk between individuals is determined very early in life, maybe even prior to 
birth. 
Heterogeneity may be due to stochastic processes 
Randomness 
Heterogeneity, or varying frailty, between individuals may have a number of different 
explanations: environment, genetics or epigenetics; or it may be a purely stochastic 
phenomenon. There is a growing recognition in biology that both stochastic variation and 
chaotic variation are important30. 
 
Many studies point to large individual differences that do not have obvious explanations. A 
recent paper points out a strong association between the telomere length of finches at 25 days 
and later mortality over several years.31 Kirkwood and Finch32 show that even genetically 
identical (i.e. isogenic) worms have great variation in their lifetimes. They stress the random 
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and unpredictable nature of cell damage that occurs with ageing. Epigenetic factors are also 
likely contributors to these time-dependent processes.  
 
Le and Cheng33 studied the problem of why genetically identical cells in the body vary widely 
in their storage of fat, even when there is no difference in the expression of the particular 
genes that affect this storage. They found that the differences between cells were due to 
variation occurring in a cascade of events within an insulin-signaling pathway. These 
variations were very slight at the beginning of the cascade, but led to very different results at 
the end. This phenomenon of small variations in starting conditions yielding very big 
differences in the end product is well known in mathematics and is related to nonlinear 
equations;  comprising essential elements of chaos theory. Nonlinearity is probably a common 
phenomenon in biology, and cascade phenomena would be expected to be nonlinear with 
complex feedback dynamics. 
 
In an interesting Nature letter, Frank and Nowak34 suggest a model where random mutations 
at a very young age can produce a developmental disposition to cancer. The idea is that during 
the gestational phase stem cells may mutate and then multiply randomly. If the mutation rate 
is high enough, this variation could be a dominant feature.35, 36  
 
The examples given here show that great individual variation may simply be an accumulation 
of purely random variation combined with nonlinear dynamics. 
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Smith offered a fascinating discussion of the importance of randomness in epidemiology.37 He 
asserts that epidemiology cannot capture the pervasive randomness which averages out at the 
population level. Our point here, though, is that when time is considered, there are telltale 
indications of random variation. 
Genetic variation and rare variants 
The lack of clear findings in many genome wide association (GWA) studies has led people to 
think that rare mutations might be responsible for many diseases. Rare gene combinations are 
difficult to discover in GWA studies, which may explain the apparent lack of genetic 
effects.38, 39 Also, Fletcher and Houlston40 explain how disease susceptibility may be an effect 
of common low-penetrance genes or rare gene combinations. Cirulli and Goldstein41 suggest 
that “rare variants could be the primary drivers of common diseases” and state that e.g. rare 
copy number variants “are associated with an effect on the risk of disease that  dramatically 
exceeds the effects of most common variants associated with a disease”.  
 
While a simple polygenic model, where the risk is a linear combination of a (possibly large) 
number of factors, will give a normally distributed risk like that in panel 1 of Figure 2, rare 
variants make it more likely that we will get variations of the type seen in panels 3 and 4. 
 
Epigenetic stochasticity 
During recent years, there has been growing recognition that environmental exposure affects 
cancer susceptibility through epigenetic changes, in addition to the traditional gene-
environment interactions, which can promote mutations. This is particularly relevant in the 
developmental origins of health and disease hypothesis.42 Some authors argue for a paradigm 
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shift, where the old view on the importance of DNA mutations is weighed down and 
supplemented by the modern view of epigenetic modifications.43 There is, however, 
indication of an important stochastic component to these modifications, and it has even been 
speculated that the majority of important epigenetic changes may not be due to the 
environment, but to random events early in life.43 This might explain the large variation that is 
often observed between genetically identical individuals.44 
 
The competing explanations: frailty selection versus biological 
mechanism 
Frailty explanations of observed incidence rates will typically attribute certain findings to 
statistical selection effects. A disease where frailty is likely to play a role is testicular cancer. 
The incidence of this disease is typical of cancer forms originating in early (fetal) life, 
reaching a peak at a rather young age (approx. 30 years) and then declining sharply. A 
reasonable explanation for this observation is that some men are susceptible to, and have an 
increased risk of acquiring testicular cancer, and do so relatively early. The declining 
incidence of testicular cancer with age is presumed to be due to high-risk individuals being 
selected out from the population after they acquire the disease. This in fact fits well with 
biological evidence suggesting that testicular cancer may be caused by cellular damage during 
fetal life, which has been used as a basis for a so-called frailty analysis of incidence.4 In fact, 
the origin of testicular cancer is believed to be carcinoma in situ cells, the malignant 
transformation of which is initiated during early development from primordial germ cells, or 
gonocytes that either fail to end their proliferation or undergo proper differentiation.45 Since 
the incidence rate of testicular cancer also has increased substantially during the last decades, 
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this damage appears to have become more prevalent over time. It should be noted that this 
kind of a statistical explanation typically competes with a biological mechanistic one. It has 
also been suggested that the decline in the risk of testicular cancer with age could be due to a 
declining testosterone level. Although the surge in testosterone level during puberty is 
important for the transformation of dormant carcinoma in situ cells to invasive testicular 
cancer, there is no evidence that individual testosterone level is a risk factor for testicular 
cancer.46 Furthermore, the decline in testosterone is rather modest from the age of 30 years. 
 
On the other hand, there are clearly cases where frailty is not the major cause of the decline in 
risk. One example is retinoblastoma, where there are almost no cases in individuals over 10 
years of age. The likely explanation is that the retinoblasts are fully differentiated at the age of 
10, and thus thereafter are not susceptible to malignant transformation.47  However, in his 
seminal study on retinoblastoma, Knudson actually took varying frailty into account.48 Long 
before the Rb1 gene was identified, he separated a very frail group (those with an inherited 
germ line mutation) from a less frail group (those who had the non-hereditary form), and used 
this to formulate his famous two-hit hypothesis. The case of retinoblastoma is thus an 
example of how the consideration of varying frailty combined with biological knowledge may 
provide valuable insights.  
 
Competing frailty and biologic mechanistic explanations are often suggested, and it may not 
be obvious which one is correct. Part of the difficulty is that when frailty is estimated from 
single event data (e.g. the single occurrence of a specific type of cancer for an individual), 
there will necessarily be uncertainty. A much more precise assessment of frailty can be done 
14 
 
in a setting where there are repeated events (e.g. cancer in both breasts, or in the kidneys or 
testicles), or when studying cancer incidence in families, e.g. testicular cancer among 
brothers.6, 7 
Familial cancer risk points to large individual heterogeneity 
For many diseases there is a familial association in risk. A surprising and counterintuitive 
issue is that even a moderate familial association points towards a large variation in risk 
between families. Hence, the existence of a familial association is another argument for the 
presence of considerable individual heterogeneity in risk. 
 
There is generally a familial association when it comes to cancer risk. For example, in breast 
cancer the genes BRCA1 and BRCA2 confer a very high familial risk. But even in the 
absence of such genes, sizeable familial association is still observed. Johns and Houlston49 
pointed out that having a first-degree relative with colorectal cancer more than doubles one’s 
risk for the disease, while the risk is increased more than 4-fold when one has two first-degree 
relatives with CRC. The risk of testicular cancer for a brother of a case is increased about 6-
fold.6, 7 Tumors of the nervous-system also show a strong heritability (standardized incidence 
ratios around 2, but up to 27 for the rare multiplex families).50 
 
Even familial risks that appear modest, like the relative risk of about 2 seen for relatives of 
breast or colon cancer patients, still imply a large variation in risk between individuals.50-52  
This has also been pointed out by Moger et al.,7 and by Aalen53 in a cardiovascular disease 
setting. In fact the variation in individual risk when even small familial risks are observed will 
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typically be of the type in panels 3 and 4 of Figure 2. An interesting quote from Hopper51 
stresses this surprising fact:  
“… even for a disease for which there is only what one might consider in epidemiological terms 
‘modest’ familial aggregation (such as a two-fold increased risk for close relatives of affecteds), people 
of the same age  and sex must differ greatly in their familial risks of disease (e.g. a 20-fold or more 
difference in risk between the quarter of the population at lowest familial risk and the quarter of the 
population at greatest familial risk). This familial risk gradient is in addition to differences due to ‘non-
familial’ environmental or lifestyle factors that are specific to individuals. Finding the causes of even a 
modest proportion of familial aggregation of a disease could be a major step in understanding the causes 
of the disease itself.” 
 
Let us consider a very simple situation: Assume that the population is divided into two groups 
of equal size, and such that the probability of acquiring a specific disease is 1% in one group 
and 20% in the other. All the members of a given family belong to the same group, be it the 
high-risk or low-risk group. Consider that the familial relative risk is defined as follows: the 
conditional probability of developing the disease if a specific family member has acquired it, 
divided by the average risk of getting the disease. In our example the familial relative risk 
equals 1.82. Hence a relative risk of 20 at the individual level translates into a very modest 
familial risk just as suggested by Hopper.51 
 
Since familial relationships are important for disease risk, it is useful to use study designs that 
to some extent control for such relationships. Within-pair twin studies are useful in this 
regard.54  
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Statistical models for familial risk 
In order to get a deeper understanding one has to consider statistical models. The familial risk 
association depends on two conditions, namely the correlation between the risk factors within 
a family, and the variation in risk within the population associated with these factors. Assume 
that the risk depends exponentially on normally distributed risk factors with a correlation ȡ, 
and that s denotes the relative risk associated with a change in the risk factor from mean – 
2SD to mean + 2SD. The familial relative risk, r, associated with a diseased sibling is given 
by 
ݎ ൌ ሼߩሺ ݏሻଶȀͳ͸ሽ,     (1) 
a special case of a more general formula given by Aalen.53 Assume for instance that ȡ = 0.5 
which is a very strong familial correlation. Then formula (1) as a function of s is plotted in 
Figure 3. One sees that even for s = 10 which represent a very strong effect of the risk factor, 
the value of r is still less than 1.2. Hence, for simple polygenetic inheritance at the risk factor 
level, the familial relative risk associated with even strong risk factors is very moderate. 
 
In practice, familial association will have several sources, partly genetic, and partly a shared 
environment or culture, or attitude toward various risk behaviors. It can be shown that 
environmental influences contribute only very slightly to the observed familial risk 
association. However, measured risk factors could be poor surrogates for risk factors that are 
more strongly familial, and the effect could be somewhat prone to e.g. measurement error. 52 
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Formula (1) presumes a normal distribution, which one would usually assume for simple 
polygenetic inheritance. Some skewness might be introduced, which might appear more 
realistic if some genes have a stronger effect than others, for example due to higher 
penetrance. We shall assume that two individuals have a common risk component which is 
gamma distributed with shape parameter ߜ. Following Aalen53, the familial relative risk, rF, is 
given by: 
ݎி ൌ ቄͳ ൅ ୪୬௥ఋିଶሺఋ ୪୬ ௥ሻభȀమቅ
ఋ
     (2) 
Note that when the shape parameter ߜ goes to infinity, this expression will converge to r 
(because an infinite ߜ implies a normal distribution for the common component). Plots of 
formula (2) as a function of ߜ and r are given in Figure 4. The major deviation occurs for 
ߜ ൌ ͳ which corresponds to an exponential distribution of the common familial risk. This 
represents a high degree of skewness (Figure 5). It means that members of a minority of 
families have a much higher risk than others. Figure 5 also includes an illustration of an even 
more skewed gamma distribution. 
 
Similar results are presented in Moger et al.7 where a totally different mathematical model 
also indicated that even a very skewed familial frailty distribution will result in very moderate 
familial relative risks. The paper presents the following useful formula 
ܴ ൌ ܥܸଶ ൅ ͳ 
where CV is the coefficient of variation of the probability of being susceptible, as it varies 
between families, and R is the relative risk of another member of the family acquiring the 
disease if there is already a case in the family. From the above formula it is seen that 
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assuming e.g. R = 2 implies CV = 1. This means that the standard deviation equals the 
expectation, which again implies a strongly skewed distribution. If the distribution comes 
from the gamma family, then it has to be an exponential distribution. If CV is greater than 1, 
then the shape parameter of the gamma distribution is less than 1 which yields an extremely 
skewed distribution (Figure 5). In fact the cases discussed here correspond to panels 3 and 4 
of Figure 2.  
 
The conclusion from this brief review of familial association is that a familial relative risk of 
2 or above is a strong indication for the existence of high risk groups of individuals. 
Interpretation of epidemiological measures 
Taking heterogeneity, or varying frailty, between individuals into account can be of crucial 
importance for the understanding of epidemiological features in a population. There is a 
natural tendency to assume that hazard rates and incidence rates can be taken at face value. 
Although these concepts appear to be simple, their interpretation can still be very difficult. 
The statistical interest in frailty stems in part from the fact that it can lead to curious statistical 
artefacts. 
 
Cross-over effects 
Consider two groups of individuals with hazard rates ߙሺݐሻ andʹߙሺݐሻ, such that the hazard 
ratio is 2. In each of these groups there would necessarily be some unobserved heterogeneity 
between individuals. By introducing equally distributed frailty variables in the two groups, a 
decreasing hazard ratio over time may be obtained. Depending on the choice of frailty 
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distribution, the hazard ratio may even cross-over, and become lower than 1, such that the 
high-risk group appears to become the low-risk group (Figure 6).  The decrease (and possible 
cross-over) of the hazard ratio over time is a frailty effect. Individuals in the high-risk group 
will on average experience events earlier than those in the low-risk group. This causes the 
proportion of highly susceptible individuals in the high-risk group to decrease faster than in 
the low-risk group, leaving an increasing proportion of less susceptible individuals. Thus, the 
hazard ratio will decrease. If, for instance, the population contains a non-susceptible 
subgroup, then the susceptible individuals in the high-risk group would be exhausted earlier 
than in the low-risk group, causing the relative risk to cross-over, and become lower than one, 
even if the hazard ratio stays constant on the individual level. This means that when frailty is 
not observed and cannot be accounted for, a wrong conclusion could be drawn regarding the 
true relationship between two groups. This is in fact a time-dependent version of Simpson’s 
paradox, which means that the observed relationship (concerning e.g. risk of disease) between 
two groups is reversed at an aggregate level compared to what would be observed at a more 
detailed level if covariates could be conditioned on. 
 
Another interesting effect of frailty occurs when discontinuing treatment in a clinical trial. Let 
us assume that the treatment group has hazard rate ߙሺݐሻ and the control group has hazard 
rateʹߙሺݐሻ, presuming the treatment is effective. At the start of the study, the hazard ratio is 
two. Because the treatment is effective, patients in the control group will on average have 
events earlier than in the treatment group, and the hazard ratio will decrease with time. At 
some point the difference between the hazard rates is so small that it is decided treatment is no 
longer effective, and it is stopped. A possible consequence of this decision is that the hazard 
ratio drops below one, and it appears protective to be a member of the control group (Figure 
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7). In the control group the most frail individuals would already have had an event at this 
point, and at the time of discontinuing the treatment, there would be a higher proportion of  
less frail individuals in the control group. In the treatment group, frail individuals that would 
already have had an event if they had not been treated, have a very high risk immediately after 
the treatment is stopped. Not being aware of a possible frailty effect may lead to a wrong 
impression of the effect of discontinuing a treatment for an individual. 
 
False protectivity 
In a competing risks framework, two (or more) events compete in determining the failure of 
an individual. The failure rate of each cause is expressed in terms of a cause-specific hazard 
rate. As in the example above, the hazard rates may be influenced by frailties. If these frailties 
are correlated, then one may observe a false protectivity.55 If a covariate has a detrimental 
effect on one of the two competing risks, it may, at the population level, appear to be 
protective in the other cause-specific hazard rate.  
Frailty and models of carcinogenesis 
The famous multi-stage model of Armitage and Doll set the stage for a mathematical 
approach to understanding cancer incidence, and it continues to play a fundamental role in our 
understanding of the carcinogenic process. This was exemplified by the re-publication of the 
original article in the International Journal of Epidemiology at its 50 year anniversary in 
2004. Since it was first suggested, however, more sophisticated models have been published. 
Moolgavkar and Knudson proposed a two-hit model (combined with clonal expansion of 
initiated cells) that took heterogeneity of the carcinogenic process itself into account, and 
explained peaking incidence rates of certain cancers by the varying (decreasing) number of 
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stem cells susceptible to mutation. Their model has later been expanded to allow for a cell to 
undergo several transitions before going into the clonal expansion phase,56 as well as other 
further developments of the model.57, 58  All these models were created to facilitate the 
understanding of cancer development on an individual level. Meza et al. studied the effect of 
gestational mutations on cancer risk, and stated that “Even with identical gestational mutation 
rates in all individuals in a population, at birth individuals are at different risk because of 
random variation in the number of mutated cells at birth”.35 Taking varying frailty into 
account (i.e. heterogeneity in risk between individuals), a Weibull hazard rate, as suggested 
by the Armitage-Doll model, makes sense. This is the case, even when assuming clonal 
expansion at some intermediate step. A mathematical formulation is that, on the individual 
level, the hazard rate of an event is given as a product of the Weibull hazard and an individual 
frailty factor. As opposed to the exhaustion of susceptible stem cells within the individual, the 
model considers the exhaustion of initially highly susceptible individuals as an explanation of 
a peaking incidence curve. This approach may also be modified in several ways, including 
taking into account an expanding host tissue during e.g. puberty.59  An important element is 
thus to combine models of carcinogenesis with a realistic understanding of individual 
differences,5, 59, 60 to better understand features of population age-incidence rates. 
 
Interpretation of incidence rates 
It turns out that also changes in epidemiological incidence rates over calendar time can be 
wrongly interpreted if one does not take into consideration the possible heterogeneity between 
individuals. Consider the simple Armitage-Doll multistage model of carcinogenesis, which 
states that a cell has to go through a certain number of transitions to reach malignancy. As an 
example, consider the simple version of a multi-stage model as shown in Figure 8. Assume 
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that the transition rates are not the same for all individuals, but that there is a strong variation 
in susceptibility. Consider for instance a population where only a small subgroup is 
susceptible to the cancer in question, and the majority has a zero rate of cancer initiation 
(transition from a normal cell to an intermediate cell). If the initiation rate increases abruptly 
at a given point in (calendar) time, the incidence rate may increase to a peak, then drop and 
stabilize on a higher level. This is illustrated in Figure 9a, for the simple multistage model in 
Figure 8, with only 1% of the population being susceptible. The same point, with 90% being 
susceptible, is illustrated in Figure 9b. Although a simplification, the abrupt increase in the 
initiation rate could be the result of a risk factor that becomes more pronounced in the 
population at a given time. 
 
The above example is simple, but illustrate that changes in the prevalence of risk factors may 
have an impact on observed incidence rates, even a long time after the change occurred. 
While the real biological change here was an abrupt increase in the prevalence of a risk factor, 
the observed incidence rates gave the impression of a risk that first increased and then 
decreased. It is of course more likely that the presence of risk factors changes gradually over 
time, and this will have a similar effect on observed incidence rates as in the above example. 
The observed incidence rate will continue to change after the prevalence of the risk factor has 
stabilized. If a cell requires more events to become malignant, changes in prevalence of 
different risk factors may affect the transition rates to various states. This could possibly also 
lead to multimodal shapes of hazard rates.  
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The point we are making, is that changes in the incidence rate may not be a simple reflection 
of what is happening at a biological level. It is well known that underlying effects will be 
smoothed out in the observed incidence. But in addition to this, frailty may produce incidence 
rates with aspects that are unrepresentative of the underlying changes. Care should be taken 
before drawing conclusions on an individual level based on observations in a population. 
 Conclusion 
We have pointed out a number of findings that indicate the presence of a considerable 
individual variation in the risk of cancer and other diseases that goes beyond what is due to 
measured risk factors. Varying frailty may create artefacts when studying incidence rates and 
other epidemiological measures, such as a decline in incidence due to the frailest individuals 
experiencing the event early. 
 
Familial associations that appear moderate may cover a large underlying variation in risk 
between individuals. This and other aspects of individual variation point towards caution in 
interpretation. The presence of individual heterogeneity cannot be ignored. It may be 
necessary to perform mathematical modeling to get a proper understanding of the nature and 
magnitude of the phenomenon of frailty in any given study population. 
 
Funding 
This work was partially supported by a grant from the Norwegian Research Council 
(191460/V50), and by the Norwegian Cancer Society, project/grant number 171851. 
 
24 
 
References 
 
 
1. Hougaard P. Analysis of Multivariate Survival Data. New York, NY: Springer-Verlag, 2000. 
2. Aalen OO, Borgan Ø, Gjessing HK. Survival and Event History Analysis: A process Point of 
View. New York, NY: Springer, 2008. 
3. Svensson E, Rogvin M, Hultman CM, Reichborn-Kjennerud T, Sandin S, Moger TA. 
Schizophrenia susceptibility and age of diagnosis - A frailty approach. Schizophr Res 2013; 
147: 140-6. 
4. Aalen OO, Tretli S. Analyzing incidence of testis cancer by means of a frailty model. Cancer 
Causes Control 1999; 10: 285-92. 
5. Moger TA, Aalen OO, Halvorsen TO, Storm HH, Tretli S. Frailty modelling of testicular cancer 
incidence using Scandinavian data. Biostatistics 2004; 5: 1-14. 
6. Valberg M, Grotmol T, Tretli S, Veierod MB, Moger TA, Aalen OO. A Hierarchical Frailty Model 
for Familial Testicular Germ-Cell Tumors. Am J Epidemiol 2013. [Epub ahead of print]. 
7. Moger TA, Aalen OO, Heimdal K, Gjessing HK. Analysis of testicular cancer data using a frailty 
model with familial dependence. Stat Med 2004; 23: 617-32. 
8. Moger TA, Haugen M, Yip BH, Gjessing HK, Borgan Ø. A hierarchical frailty model applied to 
two-generation melanoma data. Lifetime Data Anal 2011; 17: 445-460. 
9. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008 v2.0, Cancer 
Incidence and Mortality Worldwide: IARC CancerBase No. 10. [Internet]. Lyon, France: 
International Agency for Research on Cancer, 2010.  http://globocan.iarc.fr (18 June 2013, 
date last accessed). 
10. Ollberding NJ, Nomura AM, Wilkens LR, Henderson BE, Kolonel LN. Racial/ethnic differences 
in colorectal cancer risk: the multiethnic cohort study. Int J Cancer 2011; 129: 1899-906. 
11. Balmain A, Gray J, Ponder B. The genetics and genomics of cancer. Nat Genet 2003; 33 Suppl: 
238-44. 
12. Peto J, Mack TM. High constant incidence in twins and other relatives of women with breast 
cancer. Nat Genet 2000; 26: 411-4. 
13. Falk RS, Hofvind S, Skaane P, Haldorsen T. Second events following ductal carcinoma in situ of 
the breast: a register-based cohort study. Breast Cancer Res Treat 2011; 129: 929-38. 
14. Win AK, Macinnis RJ, Hopper JL, Jenkins MA. Risk prediction models for colorectal cancer: a 
review. Cancer Epidemiol Biomarkers Prev 2012; 21: 398-410. 
15. Dowty JG, Win AK, Buchanan DD, et al. Cancer risks for MLH1 and MSH2 mutation carriers. 
Hum Mutat 2013; 34: 490-7. 
16. Landvik NE, Zienolddiny S, Skaug V, Haugen A. Gene variants and lung cancer risk. BMC 
Proceedings 2010; 4(Suppl 2):. 
17. Forsdahl A. Are poor living conditions in childhood and adolescence an important risk factor 
for arteriosclerotic heart disease? Br J Prev Soc Med 1977; 31: 91-5. 
18. Ravelli GP, Stein ZA, Susser MW. Obesity in young men after famine exposure in utero and 
early infancy. N Engl J Med 1976; 295: 349-53. 
19. Kermack WO, McKendrick AG, McKinlay PL. Death-rates in Great Britain and Sweden: 
Expression of Specific Mortality Rates as Products of Two Factors, and some Consequences 
thereof. J Hyg (Lond) 1934; 34: 433-57. 
25 
 
20. Smith GD, Kuh D. Commentary: William Ogilvy Kermack and the childhood origins of adult 
health and disease. Int J Epidemiol 2001; 30: 696-703. 
21. Barker DJ, Winter PD, Osmond C, Margetts B, Simmonds SJ. Weight in infancy and death 
from ischaemic heart disease. Lancet 1989; 2: 577-80. 
22. Barker DJ, Osmond C. Infant mortality, childhood nutrition, and ischaemic heart disease in 
England and Wales. Lancet 1986; 1: 1077-81. 
23. van der Pols JC, Bain C, Gunnell D, Smith GD, Frobisher C, Martin RM. Childhood dairy intake 
and adult cancer risk: 65-y follow-up of the Boyd Orr cohort. Am J Clin Nutr 2007; 86: 1722-9. 
24. Eriksson JG, Kajantie E, Osmond C, Thornburg K, Barker DJ. Boys live dangerously in the 
womb. Am J Hum Biol 2010; 22: 330-5. 
25. Thompson RF, Einstein FH. Epigenetic basis for fetal origins of age-related disease. J Womens 
Health (Larchmt) 2010; 19: 581-7. 
26. Pearson H. Study of a lifetime. Nature 2011; 471: 20-4. 
27. Painter RC, Osmond C, Gluckman P, Hanson M, Phillips DI, Roseboom TJ. Transgenerational 
effects of prenatal exposure to the Dutch famine on neonatal adiposity and health in later 
life. BJOG 2008; 115: 1243-9. 
28. Verhoeven R, Houterman S, Kiemeney B, Koldewijn E, Coebergh JW. Testicular cancer: 
marked birth cohort effects on incidence and a decline in mortality in southern Netherlands 
since 1970. Int J Cancer 2008; 122: 639-42. 
29. Bergström R, Adami HO, Mohner M, et al. Increase in testicular cancer incidence in six 
European countries: a birth cohort phenomenon. J Natl Cancer Inst 1996; 88: 727-33. 
30. Strogatz SH. Nonlinear dynamics and chaos: with applications to physics, biology, chemistry, 
and engineering (Studies in Nonlinearity). Cambridge, MA: Perseus Books Group, 2001. 
31. Heidinger BJ, Blount JD, Boner W, Griffiths K, Metcalfe NB, Monaghan P. Telomere length in 
early life predicts lifespan. Proc Natl Acad Sci U S A 2012; 109: 1743-8. 
32. Kirkwood TB, Finch CE. The old worm turns more slowly. Nature 2002; 419: 794-95. 
33. Le TT, Cheng JX. Single-cell profiling reveals the origin of phenotypic variability in 
adipogenesis. PLoS One 2009; 4: e5189. 
34. Frank SA, Nowak MA. Developmental predisposition to cancer. Nature 2003; 422: 494. 
35. Meza R, Luebeck EG, Moolgavkar SH. Gestational mutations and carcinogenesis. Math Biosci 
2005; 197: 188-210. 
36. Frank SA. Evolution in health and medicine Sackler colloquium: Somatic evolutionary 
genomics: mutations during development cause highly variable genetic mosaicism with risk 
of cancer and neurodegeneration. Proc Natl Acad Sci USA 2010; 107 Suppl 1: 1725-30. 
37. Smith GD. Epidemiology, epigenetics and the 'Gloomy Prospect': embracing randomness in 
population health research and practice. Int J Epidemiol 2011; 40: 537-62. 
38. Maher B. Hiding place for missing heritability uncovered. Nature 2010. doi: 
10.1038/news.2010.33 
39. Dickson SP, Wang K, Krantz I, Hakonarson H, Goldstein DB. Rare variants create synthetic 
genome-wide associations. PLoS Biol 2010; 8: e1000294. 
40. Fletcher O, Houlston RS. Architecture of inherited susceptibility to common cancer. Nat Rev 
Cancer 2010; 10: 353-61. 
41. Cirulli ET, Goldstein DB. Uncovering the roles of rare variants in common disease through 
whole-genome sequencing. Nat Rev Genet 2010; 11: 415-25. 
42. Walker CL, Ho SM. Developmental reprogramming of cancer susceptibility. Nat Rev Cancer 
2012; 12: 479-86. 
43. Petronis A. Epigenetics as a unifying principle in the aetiology of complex traits and diseases. 
Nature 2010; 465: 721-7. 
44. Finch CE, Kirkwood TBL. Chance, Development, and Aging. New York, NY: Oxford University 
Press, 2000. 
26 
 
45. McGlynn KA, Cook MB. Etiologic factors in testicular germ-cell tumors. Future Oncol 2009; 5: 
1389-402. 
46. Swerdlow AJ, Huttly SR, Smith PG. Testis cancer: post-natal hormonal factors, sexual 
behaviour and fertility. Int J Cancer 1989; 43: 549-53. 
47. Chial H. Tumor Suppressor (TS) Genes and the Two-Hit Hypothesis. Nature Education 2008; 1: 
177. 
48. Knudson AG. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 
1971; 68: 820-3. 
49. Johns LE, Houlston RS. A systematic review and meta-analysis of familial colorectal cancer 
risk. Am J Gastroenterol 2001; 96: 2992-3003. 
50. Hemminki K, Tretli S, Sundquist J, Johannesen TB, Granström C. Familial risks in nervous-
system tumours: a histology-specific analysis from Sweden and Norway. Lancet Oncol 2009; 
10: 481-8. 
51. Hopper JL. Disease-specific prospective family study cohorts enriched for familial risk. 
Epidemiol Perspect Innov 2011; 8: 2. 
52. Hopper JL, Carlin JB. Familial aggregation of a disease consequent upon correlation between 
relatives in a risk factor measured on a continuous scale. Am J Epidemiol 1992; 136: 1138-47. 
53. Aalen OO. Modelling the influence of risk-factors on familial aggregation of disease. 
Biometrics 1991; 47: 933-45. 
54. Stone J, Dite GS, Giles GG, Cawson J, English DR, Hopper JL. Inference about causation from 
examination of familial confounding: application to longitudinal twin data on mammographic 
density measures that predict breast cancer risk. Cancer Epidemiol Biomarkers Prev 2012; 21: 
1149-55. 
55. Di Serio C. The protective impact of a covariate on competing failures with an example from 
a bone marrow transplantation study. Lifetime Data Anal 1997; 3: 99-122. 
56. Luebeck EG, Moolgavkar SH. Multistage carcinogenesis and the incidence of colorectal 
cancer. Proc Natl Acad Sci U S A 2002; 99: 15095-100. 
57. Jeon J, Meza R, Moolgavkar SH, Luebeck EG. Evaluation of screening strategies for pre-
malignant lesions using a biomathematical approach. Math Biosci 2008; 213: 56-70. 
58. Meza R, Jeon J, Moolgavkar SH, Luebeck EG. Age-specific incidence of cancer: Phases, 
transitions, and biological implications. Proc Natl Acad Sci USA 2008; 105: 16284-9. 
59. Valberg M, Grotmol T, Tretli S, Veierød MB, Devesa SS, Aalen OO. Frailty modeling of age-
incidence curves of osteosarcoma and Ewing sarcoma among individuals younger than 40 
years. Stat Med 2012; 31: 3731-47. 
60. Haugen M, Bray F, Grotmol T, Tretli S, Aalen OO, Moger TA. Frailty modeling of bimodal age-
incidence curves of nasopharyngeal carcinoma in low-risk populations. Biostatistics 2009; 10: 
501-14. 
 
  
Figure 1: Colorectal cancer incidence in various regions. Picture constructed by Globocan.9 
 
 
 
 
 
 
 Figure 2: Various types of distributions of risk (frailty) at an early age: (1) small variation in risk 
between individuals, (2) large group at moderate risk, and a smaller group of individuals at high risk, 
(3) very skewed: many individuals at low risk and a small group at high risk, (4) most individuals at 
close to zero risk and a few individuals at a high risk. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 3: The familial relative risk, r, associated with a diseased sibling as a function of s according to 
formula (1) in the text, where s denotes the relative risk associated with a change in a risk factor 
from mean minus two standard deviations to mean plus two standard deviations. Based on normally 
distributed variation in risk. 
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 Figure 4: The familial relative risk, ݎி, associated with a diseased sibling as a function of r according 
to formula (2) in the text, where the two individuals in the family have a common risk component 
that is gamma distributed with shape parameter ߜ. Here r is the familial relative risk from formula 
(1), that is the familial relative risk without the skewness introduced by the common, gamma 
distributed component. ݎி is plotted for given values of ߜ. Note that ߜ ՜ λ implies ݎி ൌ ݎ. 
 
 
 
 
 
 
 Figure 5: Probability densities for the exponenetial distribution (solid line) and the gamma 
distribution with shape parameter 0.5 (dashed line). 
 
 
 
 
 
 
 
 
  
 
Figure 6: Assume that the hazard rates in two risk groups are ߙሺݐሻ and ʹߙሺݐሻ respectively. When 
frailty variables are introduced, the observed relative risk declines over time as shown in the figure. 
Three frailty distributions are used; one leads to a crossover of the hazard ratio. This case 
corresponds to a frailty distribution with a positive probability of zero frailty (i.e. a non-susceptible 
group). See Aalen et al.2, Chapter 6, for technical details. 
 
 
 
 
 
 
 
  
 
 
Figure 7: Effect of discontinuing treatment. A control group with hazard rate ʹߙሺݐሻ is compared with 
a treatment group with hazard rate ߙሺݐሻ. Treatment is discontinued at time point 1.
  
Figure 8: Simple illustration of an Armitage-Doll multi-stage model of carcinogenesis. The states 
represent the stages of the carcinogenic process. State one is the healthy state, state two is an 
intermediate state, and in state three a malignant cell has developed. State four is a censored state. 
The ߙs and ߤs are transition rates. 
 
 
 
 
 
Figure 9: Incidence rates for the model in Figure 8. Assume that 10,000 individuals enter state one 
per time unit. The transition rates are ߙଵ ൌ ͲǤͲͳ for time ൏ ʹͲ, and ߙଵ ൌ ͲǤͲ͵ for time ൒ ʹͲ. Also, 
ߙଶ ൌ ͲǤͲʹ, ߤଵ ൌ ͲǤͲͳ and ߤଶ ൌ ͲǤͲͷ   a) 1% of the population is susceptible, i.e. having ߙଵ ് Ͳ. b) 
90% of the population is susceptible, i.e. having ߙଵ ് Ͳ. 
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